

**PRM-35-19  
(71FR34285)**

**From:** "Oliver W. Press" <press@u.washington.edu>  
**To:** <SECY@nrc.gov>  
**Date:** Tue, Aug 21, 2007 11:21 AM  
**Subject:** PRM-35-19

DOCKETED  
USNRC

August 21, 2007 (2:30pm)

OFFICE OF SECRETARY  
RULEMAKINGS AND  
ADJUDICATIONS STAFF

August 20, 2007

26

Annette L. Vietti-Cook, Secretary

US Nuclear Regulatory Commission

Washington, DC 20555

Attn: Rulemaking and Adjudication Staff

RE: Comments to Petition for Rulemaking Submitted by Dr. Stein, Docket No. PRM-35-19

Dear Ms. Cook,

I am sending this letter in strong support of the Petition for Rulemaking (PRM) submitted by Dr. Stein (PRM-35-19) which would amend the NRC regulations and would permit hematologists and oncologists to attain AU status for the administration of Quadramet, Bexxar, and Zevalin after an 80-hour training period. This petition is consonant with NRC's current regulations that permit any physician, including endocrinologists, to administer oral Na131 to treat thyroid disorders with only 80 hours of classroom and laboratory training. We believe that Quadramet, Bexxar, and Zevalin pose less of a radiation hazard than oral I131 administration, which is already permitted by the NRC. I recognize that associated nuclear imaging studies would need to be performed by a nuclear medicine physician or radiation oncologist, but the imaging component is a separate issue from the one addressed by this letter. In summary, I strongly urge you to approve this petition to facilitate the delivery of Bexxar and Zevalin, which are highly effective agents for the treatment of lymphoma, that are currently underutilized because of their limited availability in the community. Please do not hesitate to contact me if I can provide further information.

Sincerely,

Oliver W. Press, MD, PhD

Member, The Fred Hutchinson Cancer Research Center

Template = SECY-067

SECY-02

Recipient, Dr. Penny E. Petersen Memorial Chair for Lymphoma Research

Professor of Medicine and Biological Structure

University of Washington

Director, Clinical Research in Hematology and Hematologic Malignancies

Seattle Cancer Care Alliance

**CC:** <nukephysics@comcast.net>, <mkaminsk@umich.edu>

**Mail Envelope Properties** (46CB02D8.104 : 0 : 37124)

**Subject:** PRM-35-19  
**Creation Date** Tue, Aug 21, 2007 11:20 AM  
**From:** "Oliver W. Press" <[press@u.washington.edu](mailto:press@u.washington.edu)>

**Created By:** [press@u.washington.edu](mailto:press@u.washington.edu)

**Recipients**

nrc.gov

TWGWPO02.HQGWDO01  
 SECY (SECY)

umich.edu

mkaminsk CC

comcast.net

nukephysics CC

**Post Office**

TWGWPO02.HQGWDO01

**Route**

nrc.gov  
 umich.edu  
 comcast.net

<b>Files</b>	<b>Size</b>	<b>Date &amp; Time</b>
MESSAGE	1864	Tuesday, August 21, 2007 11:20 AM
TEXT.htm	7256	
Mime.822	12476	

**Options**

**Expiration Date:** None  
**Priority:** Standard  
**ReplyRequested:** No  
**Return Notification:** None

**Concealed Subject:** No  
**Security:** Standard

**Junk Mail Handling Evaluation Results**

Message is eligible for Junk Mail handling  
 This message was not classified as Junk Mail

**Junk Mail settings when this message was delivered**

Junk Mail handling disabled by User

Junk Mail handling disabled by Administrator  
Junk List is not enabled  
Junk Mail using personal address books is not enabled  
Block List is not enabled